Clinical Trials Using Hafnium Oxide-containing Nanoparticles NBTXR3
Clinical trials are research studies that involve people. The clinical trials on this list are studying Hafnium Oxide-containing Nanoparticles NBTXR3. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
This study is a Phase 1 / 2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will receive only EBRT and the other group will receive a Brachytherapy boost and EBRT.Both groups will receive treatment with androgen deprivation. There will be 2 consecutive steps, a dose escalation and a subsequent dose expansion part.
Location: 4 locations
NBTXR3 Activated by SABR for Patients With Advanced HNSCC or NSCLC Treated With an Anti-PD1 Antibody
The study is an open label Phase I / II prospective clinical trial, non randomized, which consists of two consecutive steps, a dose escalation and a subsequent dose expansion part. The phase I and II parts include different patient population.
Location: Moffitt Cancer Center, Tampa, Florida